IDXX · Idexx Laboratories Inc · Webcasts, Transcripts & Audio
$704.23
+6.21 (+0.89%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$55.48B
Shares
78.79M
Volume · Nov 13
392.85K
Avg daily vol (3M)
568.44K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Idexx Laboratories Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Idexx Laboratories Inc (IDXX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-02
Idexx Laboratories Inc (IDXX) Q3 2026 Earnings Call Transcript
Confident tone
CancerDX expansion
InViewDX placements and menu expansion
CoVet acquisition and AI-enabled software
Revenue
$1.21B
▲ 9.9% YoY Diluted EPS
$4.01
▲ 17.9% YoY Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Idexx Laboratories Inc (IDXX) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Idexx Laboratories Inc (IDXX) Q2 2026 Earnings Call Transcript
Confident tone
CAG Diagnostics Recurring Revenue
Premium Instrument Placements & InView DX
International Growth
Revenue
$1.22B
▲ 9.7% YoY Diluted EPS
$4.27
▲ 17.6% YoY Gross margin
64.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-05
Idexx Laboratories Inc (IDXX) Q1 2026 Earnings Call Transcript
Confident tone
Companion Animal Diagnostics (CAG) Recurring Revenue
Guidance Raise / Full-Year Outlook
Premium Instrument Placements
Revenue
$1.14B
▲ 14.3% YoY Diluted EPS
$3.47
▲ 17.2% YoY Gross margin
63.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-02
Idexx Laboratories Inc (IDXX) Q4 2025 Earnings Call Transcript
Confident tone
Premium Instrument Placements (InVue DX, Catalyst, etc.)
Software / SaaS (Velo, PIMs)
2026 Financial Guidance and Margin Expansion
Revenue
$1.09B*
▲ 14.3% YoY Gross margin
60.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Idexx Laboratories Inc (IDXX) Q3 2025 Earnings Call Transcript
Confident tone
IDEXX Cancer Dx Adoption
Premium Instrument Placements and Installed Base
CAG Diagnostics Recurring Revenue Growth
Revenue
$1.11B
▲ 13.3% YoY Diluted EPS
$3.40
▲ 21.4% YoY Gross margin
61.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Idexx Laboratories Inc (IDXX) Q2 2025 Earnings Call Transcript
Confident tone
CAG Diagnostic Recurring Revenue Growth
IDEXX Cancer Dx Launch
Profitability and Margin Expansion
Revenue
$1.11B
▲ 10.6% YoY Diluted EPS
$3.63
▲ 48.8% YoY Gross margin
62.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Idexx Laboratories Inc (IDXX) Q1 2025 Earnings Call Transcript
Positive tone
IDEXX inVue Dx platform launch
U.S. clinical visit headwinds
Organic revenue growth and execution
Revenue
$998.43M
▲ 3.6% YoY Diluted EPS
$2.96
▲ 5.3% YoY Gross margin
62.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-03
Idexx Laboratories Inc (IDXX) Q4 2024 Earnings Call Transcript
Confident tone
Organic revenue growth
Innovation / new product launches
Operating margin and gross margin
Revenue
$954.29M*
▲ 5.8% YoY Gross margin
59.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Idexx Laboratories Inc (IDXX) Q3 2024 Earnings Call Transcript
Positive tone
CAG diagnostic recurring revenue
IDEXX In View / In Vue analyzer launch
US macro and sector headwinds
Revenue
$975.54M
▲ 6.6% YoY Diluted EPS
$2.80
▲ 10.7% YoY Gross margin
61.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Idexx Laboratories Inc (IDXX) Q2 2024 Earnings Call Transcript
Positive tone
Innovation and inVue launch
CAG diagnostic recurring revenue
U.S. clinical visit headwinds
Revenue
$1.00B
▲ 6.4% YoY Diluted EPS
$2.44
▼ 8.6% YoY Gross margin
61.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Idexx Laboratories Inc (IDXX) Q1 2024 Earnings Call Transcript
Positive tone
CAG Diagnostic recurring revenue growth
Premium instrument placements and installed base
U.S. clinical visit softness and macro headwinds
Revenue
$964.10M
▲ 7.1% YoY Diluted EPS
$2.81
▲ 10.2% YoY Gross margin
61.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-05
Idexx Laboratories Inc (IDXX) Q4 2023 Earnings Call Transcript
Confident tone
CAG Diagnostic Recurring Revenue Growth
Veterinary Software and Diagnostic Imaging
2024 Financial Guidance
Revenue
$901.60M*
▲ 8.8% YoY Gross margin
58.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Idexx Laboratories Inc (IDXX) Q3 2023 Earnings Call Transcript
Revenue
$915.53M
▲ 8.8% YoY Diluted EPS
$2.53
▲ 17.7% YoY Gross margin
59.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Idexx Laboratories Inc (IDXX) Q2 2023 Earnings Call Transcript
Revenue
$943.63M
▲ 9.7% YoY Diluted EPS
$2.67
▲ 71.2% YoY Gross margin
60.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Idexx Laboratories Inc (IDXX) Q1 2023 Earnings Call Transcript
Revenue
$900.20M
▲ 7.6% YoY Diluted EPS
$2.55
▲ 12.3% YoY Gross margin
60.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-06
Idexx Laboratories Inc (IDXX) Q4 2022 Earnings Call Transcript
Revenue
$828.57M*
▲ 3.4% YoY Gross margin
58.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Idexx Laboratories Inc (IDXX) Q3 2022 Earnings Call Transcript
Revenue
$841.66M
▲ 3.9% YoY Diluted EPS
$2.15
▲ 5.9% YoY Gross margin
60.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Idexx Laboratories Inc (IDXX) Q2 2022 Earnings Call Transcript
Revenue
$860.55M
▲ 4.2% YoY Diluted EPS
$1.56
▼ 33.3% YoY Gross margin
59.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Idexx Laboratories Inc (IDXX) Q1 2022 Earnings Call Transcript
Revenue
$836.55M
▲ 7.6% YoY Diluted EPS
$2.27
▼ 3.4% YoY Gross margin
59.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-02
Idexx Laboratories Inc (IDXX) Q4 2021 Earnings Call Transcript
Revenue
$801.09M*
▲ 11.1% YoY Gross margin
57.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Idexx Laboratories Inc (IDXX) Q3 2021 Earnings Call Transcript
Revenue
$810.42M
▲ 12.3% YoY Diluted EPS
$2.03
▲ 20.1% YoY Gross margin
58.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-30
Idexx Laboratories Inc (IDXX) Q2 2021 Earnings Call Transcript
Revenue
$826.14M
▲ 29.6% YoY Diluted EPS
$2.34
▲ 36% YoY Gross margin
59.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Idexx Laboratories Inc (IDXX) Q1 2021 Earnings Call Transcript
Revenue
$777.71M
▲ 24.2% YoY Diluted EPS
$2.35
▲ 82.2% YoY Gross margin
60.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-02
Idexx Laboratories Inc (IDXX) Q4 2020 Earnings Call Transcript
Revenue
$720.94M*
▲ 19.1% YoY Gross margin
56.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Idexx Laboratories Inc (IDXX) Q3 2020 Earnings Call Transcript
Revenue
$721.79M
▲ 19.2% YoY Diluted EPS
$1.69
▲ 36.3% YoY Gross margin
58.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
Idexx Laboratories Inc (IDXX) Q2 2020 Earnings Call Transcript
Revenue
$637.59M
▲ 2.8% YoY Diluted EPS
$1.72
▲ 20.3% YoY Gross margin
59.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Idexx Laboratories Inc (IDXX) Q1 2020 Earnings Call Transcript
Revenue
$626.34M
▲ 8.7% YoY Diluted EPS
$1.29
▲ 10.3% YoY Gross margin
57.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-31
Idexx Laboratories Inc (IDXX) Q4 2019 Earnings Call
Revenue
$605.45M
▲ 10.2% YoY Diluted EPS
$1.04
▲ 6.1% YoY Gross margin
54.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 webcasts
Key facts
CIK
874716
CUSIP
45168D104
13F (30d)
1013 filings
954 filers
Visit website
Investor relations